Prognosis
BioNTech Lifts Covid Vaccine Sales Forecast to $18.7 Billion
- ADRs surge in U.S. trading on new outlook for vaccine sales
- Covid vaccine could become one of the best-selling drugs ever
Source: Pfizer Inc.
This article is for subscribers only.
BioNTech SE raised its forecast for this year’s Covid-19 vaccine sales to 15.9 billion euros ($18.7 billion) and said it’s pushing forward plans to test its messenger RNA technology in cancer.
BioNTech and partner Pfizer Inc. signed contracts to deliver some 2.2 billion doses of the two-shot vaccine this year and more than 1 billion doses in 2022 and beyond, the Mainz, Germany-based company said Monday. BioNTech had previously predicted 12.4 billion euros in 2021 revenue from its only marketed product.